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Abstract
Background
Interferon gamma (IFN-γ) production induces the transcription of indoleamine 2,3 dioxygenase
(IDO) resulting in the reduction of T-cell activation and proliferation through the depletion of
tryptophan and the elicitation of Treg lymphocytes. IDOwas shown to be involved in the patho-
genesis of autoimmune diseases; we investigated whether changes in IDO gene expression
and activity could be indicative of onset of relapse in multiple sclerosis (MS) patients.
Methods
IDO and interferon-γ (IFN-γ) gene expression, serum IDO activity (Kynurenine/Tryptophan
ratio) and serum neopterin concentration – a protein released by macrophages upon IFN-γ
stimulation – were measured in 51 individuals: 36 relapsing remitting (RR)-MS patients (21
in acute phase -AMS, 15 in stable phase -SMS) and 15 healthy controls (HC). PBMCs sam-
ples in AMS patients were collected before (BT-AMS) and during glucocorticoids-based
therapy (DT-AMS).
Results
IDO expression was increased and IFN-γ was decreased (p<0.001) in BT-AMS compared
to SMS patients. Glucocorticoids-induced disease remission resulted in a significant reduc-
tion of IDO and IFN-γ gene expression, IDO catalytic activity (p<0.001). Serum neopterin
concentration followed the same trend as IDO expression and activity.
Conclusions
Measurement of IDO gene expression and activity in blood could be a useful marker to mon-
itor the clinical course of RR-MS. Therapeutic interventions modulating IDO activity may be
beneficial in MS.
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Introduction
Multiple Sclerosis (MS) is a chronic demyelinating neurodegenerative disorder of the central ner-
vous system (CNS). This disease is characterized by perivascular inflammatory lesions in the
white matter of the CNS, demyelination, and axonal damages and is probably initiated by auto-
reactive T lymphocytes directed toward CNS antigens. Activatory events occurring in the periph-
ery, as well as failure in multiple regulatory mechanisms of immune tolerance, can foster the
CNS infiltration of activated autoreactive T cells, resulting in tissue damage [1]. Relapsing remit-
ting MS (RR-MS), the most common course of the disease, is characterized by periods of worsen-
ing neurologic function (relapse) followed by phases of partial or complete recovery (remissions).
The molecular processes that lie behind the succession of these phases are only partially known.
Indoleamine 2,3 dioxygenase (IDO) is an enzyme that catalyses the first and rate-limiting
step in the kynurenine (Kyn) pathway, i.e. the degradation of the essential amino acid trypto-
phan (Trp) into Kyn in extrahepatic tissues. This pathway plays a role in the pathogenesis of
neuroinflammatory and neurodegenerative disorders. Thus, the intermediate metabolites of
Trp catabolism can modulate neurotransmitter (serotonin, melatonin) and inflammatory path-
ways in peripheral and central nervous systems, where they can have both neurotoxic and neu-
roprotective roles [2]. IDO, in particular, plays a dual function (reviewed in [3]): on one hand
it contributes to innate host defences as it directly inhibits the growth of microorganisms, on
the other hand it promotes immune tolerance, facilitating the maturation of naive T lympho-
cytes into T regulatory cells, and increasing T cell susceptibility to apoptosis. Notably, Kyn is
also endowed with immune properties as it stimulates the development and the activation of
Treg cells [4] and, as a consequence, plays a role in tolerance and immune suppression.
Both IDO and Kyn were shown to be involved in oncogenesis, viral infections, and meta-
bolic diseases. Thus, IDO over-expression in cancer [5] and in HIV disease [6] is associated
with poor prognosis, whereas glycemic parameters worsen when IDO activity is blocked in dia-
betic patients [7]. The Kyn pathway, finally, is activated during neuroinflammation and seems
to be implicated in different neurological conditions, including HIV-associated neurocognitive
disorder, as well as Parkinson’s and Alzheimer’s diseases [8].
Interferon-γ (IFN-γ) stimulates IDO gene transcription in many cell types including macro-
phages, dendritic cells and fibroblasts [9]. This also takes place in the CNS, as the microglia
expresses IDO upon treatment with IFN-γ [10, 11]. Recent evidences obtained in experimental
autoimmune encephalomyelitis (EAE), the murine model of MS, show that IDO induction
results in the down-modulation of neuroinflammation and in an improvement of the disease
[12, 13]. Moreover, an opposing pattern of IDO and IFN-γmRNA expression was observed in
spinal cord and peripheral blood mononuclear cells (PBMCs) through the preclinical, acute
and remission phases of EAE [12], suggesting that IDO and Trp metabolites contribute to the
reversible neurological symptoms of MS. Nevertheless, although Trp levels and IDO activity
have been repeatedly studied in MS patients [14–16], consistent results have not been obtained,
probably due to the variable course of the disease.
In the attempt to shed light on the role of the IDO pathway in MS we analyzed IDO, IFN-γ,
and IDO enzyme activity in PBMCs of RR-MS patients undergoing clinical relapse before and
after the initiation of glucocorticoids (GC) therapy.
Materials and Methods
Patients and controls
Fifty-one individuals were enrolled in the study: 36 patients with a diagnosis of RR-MS and 15
age- and sex- matched healthy controls (HC). All patients were diagnosed as having relapsing
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remitting MS according to revised McDonald classification [17]; HC included laboratory and
hospital staff with no history of autoimmune disease. MS patients in an acute phase of the dis-
ease (AMS, n = 21)—defined as an episode of neurological disturbance lasting for at least 24
hours and for which there was no other causes [17]—underwent clinical examination before
and after GC treatment with intravenous methylprednisolone (1g/die for 5 days administered
in two hours in the morning). The GC treatment was administered as standard care for the
patients in this study. MS patients in a stable phase (SMS, n = 15) of disease were enrolled
when free of treatment and no new neurological symptoms had been registered for at least two
months before the inclusion in the study. Stable disease was diagnosed on the basis of brain
and spinal cord magnetic resonance imaging (MRI) with gadolinium showing no areas of
enhancement at the time of enrolment. The study conformed to ethical principles of the Hel-
sinki Declaration and was approved by the local ethics committee of the Don C. Gnocchi Foun-
dation ONLUS; all patients and controls gave their written informed consent to participate in
the study.
Sample collection and RNA extraction
RNA was extracted from PBMCs after whole blood collection, while sera were stored at -20°C.
In AMS subjects, a blood sample was collected immediately before the first dose of GC
(BT-AMS) as well as after 2 days of treatment (DT-AMS). In 8 patients blood samples were
collected after one day of treatment as well and in 3 more cases, samples were also collected
after four days of therapy. Total RNA was extracted using the RNAeasy Mini extraction kit
(Qiagen, Hilden, Germany) and eluted in RNAse-Free water. Total RNA concentration was
determined by spectrophotometer (OD: 260 nm). Purity was determined as the 260 nm/280
nm OD ratio with expected values between 1.8 and 2.0. RNA was treated with TURBO DNA-
free DNAse (Ambion INC, Austin, TX, USA) and retrotranscribed with High-capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), as specified by manu-
facturers. cDNA samples were stored at –20°C until use.
Relative quantitative real-time PCR (q-PCR)
Q-PCR experiments were performed on ABI Prism 7000 Sequence Detection System (Applied
Biosystems), using pre-designed and validated primers (Applied Biosystems) for two house-
keeping genes (hkg) (GAPDH assay IDs: Hs99999905_m1, ACTB Hs99999903_m1) and IDO
(assay ID: Hs00984148_m1) and IFN-γ genes (assay ID: Hs00989291_m1) as targets.
Briefly, 2 μl of cDNA were used in a PCR reaction volume of 20 μl, containing 10 μl of Gene
Expression Master Mix (Applied Biosystem), 1μl of TaqMan probe and 7 μl of water. PCR
cycles were as follows: 10 min at 95°C followed by 40 cycles of 15°C at 95°C and 1 min at 60°C.
All reactions were performed in triplicate, with non-template control for each gene. For each
sample, relative gene expression of the target mRNA was calculated, relative to an endogenous
reference gene (ΔCqsample: Cqtarget- Cqhkg). Gene-expression levels are given as normalization
ratio calculated as: fold = 2-[ΔCq(sample)-ΔCq(control)] [18].
Sera measurements
Free Trp and Kyn serum concentrations (μM) were determined by high-performance liquid
chromatography (HPLC) [19]. The ratio of Kyn/Trp (mmol/mol) was calculated as index of
Trp breakdown. Neopterin concentrations (nM) were measured by an enzyme-linked immu-
nosorbent assay (BRAHMS Diagnostics, Berlin, Germany).
IDO in Multiple Sclerosis
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Statistical analysis
All data were normally distributed; they are reported as mean ± standard deviation (SD),
whereas mRNA expression is reported as median of folding and interquartile range (IQR). As
the main goal of this study was to compare AMS and SMS patients, SMS patients were used as
reference group for mRNA folding measurement. Analyses of RNA relative expression were
performed with the REST 2009 Software (http://www.qiagen.com/Products/
REST2009Software.aspx?r=8042), that permits to use multiple reference genes for normaliza-
tion, improving the reliability of results [20]. The expression ratio results are tested for signifi-
cance by a Pair Wise Fixed Reallocation Randomisation Test.
Data of IDO activity were analyzed with ANOVA test and, when appropriate, with the Stu-
dent’s t-test.
Results
Clinical outcome
Demographic and clinical data of the individuals included in the study are shown in Table 1.
MS patients did not differ for disease duration or for EDSS indexes. Disease remission was
achieved by GC in all AMS patients.
IDO and IFN-γmRNA expression
IDO and IFN-γmRNA expression was measured by q-PCR in PBMCs of SMS, AMS and HC
individuals. AMS patients were studied before (BT-AMS) and after the initiation of GC therapy
(DT-AMS). Results showed that, IDO expression was decreased (p = 0.01) (Fig 1, Panel A and
Table 2) whereas that of IFN-γ was increased (p<0.001) (Fig 1, Panel B and Table 2) in SMS
compared to HC. The expression of IDO was also significantly augmented in BT-AMS compared
to SMS patients (p<0.001); this was drastically modified by therapy. Thus, GC-associated disease
remission was correlated with a significant reduction of IDO expression (BT-AMS vs. DT-AMS
p<0.001; DT-AMS vs. SMS and vs. HC p<0.001). Notably, IFN-γ expression was reduced in
BT-AMS (p<0.001) compared to SMS, and decreased even more in DT-AMS (p = 0.01).
Immune activation in the different conditions was evaluated by measuring neopterin levels
as well. Results showed that serum neopterin concentration was increased, although not signifi-
cantly, in BT-AMS (5.02±1.64 nM) compared to SMS (4.81±1.12 nM) and DT-AMS (4.70
±1.10 nM) (Table 2).
The results obtained in DT-AMS individuals derive from analyses performed one day after
initiation of GC; these results were similar to those seen when samples collected 1 or 4 days
Table 1. Demographic and clinical data of the individuals enrolled in the study.
AMS SMS HC
N 21 15 15
Gender (M:F) 8:13 5:10 5:10
Age (years) 36.29±9.78 40.25±5.92 37.83±9.55
Disease duration (years) 10.66±8.15 13.43±10.41 —
EDSS 3.15±1.37 4.14±1.75 —
Data are expressed as mean ± standard deviation. AMS: multiple sclerosis patients during disease relapse;
SMS: multiple sclerosis patients in a stable phase of disease; HC: healthy controls; EDSS: expanded
disability status score; SD: standard deviation.
doi:10.1371/journal.pone.0130715.t001
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after initiation of therapy were analyzed (IDO fold: 0.06, 0.05–0.12, 1 day of treatment; 0.14,
0.09–0.58, 4 days of treatment; IFN-γ fold: 0.008, 0.003–0.013, 1 day of treatment, 0.006,
0.004–0.012, 4 days of treatment).
IDO activity
To evaluate IDO activity, the Kyn/Trp ratio was measured by HPLC in each individual. As
shown in Fig 2 and summarized in Table 2, the Kyn/Trp ratio was decreased in SMS compared
to HC, but this difference did not reach statistical significance. Interestingly, the Kyn/Trp ratio
in BT-AMS was slightly augmented compared to SMS; this ratio was nevertheless significantly
decreased by treatment (BT-AMS vs. DT-AMS: p<0.0001). Finally, the Kyn/Trp ratio was
reduced in DT-AMS compared to SMS and HC (p<0.0001), whereas no differences were
found between BT-AMS and HC. Again, no differences were seen in this parameter when
results obtained 1, 2 or 4 days of therapy were compared (Kyn/Trp mmol/mol: 26.95±4.6, 1
day of treatment, 23.85±5.54, 4 days of treatment).
Fig 1. IDO and IFN-γ gene expression.mRNA relative expression of IDO (A) and IFN-γ (B) in healthy
controls (HC) and in multiple sclerosis patients with stable (SMS) or relapsing (AMS) disease. AMS patients
were analyzed before (BT-AMS) or after the initiation of glucocorticoid treatment (DT-AMS). *p<0.05.
doi:10.1371/journal.pone.0130715.g001
Table 2. IDO gene expression and enzymatic activity and neopterin concentration in patients and healthy controls.
SMS BT-AMS DT-AMS HC
IDO (fold) 1*#¶ 4.19 0.06 4.27
(2.34–6.90) (0.03–0.13)*¶ (0.75–6.57)
IFN-γ (fold) 1*# ¶ 0.02 0.005 0.03
(0.01–0.03) (0.003–0.13)*¶ (0.02–0.05)
Kyn (μM) 2.48±0.51# 2.40±0.63# 1.85±0.35 2.65±.78#
Trp (μM) 78.80±14.11 73.69±11.63 76.89±10.77 69.21±16.40
Kyn/Trp (mmol/mol) 32.11±8.25# 34.52±11.78# 24.40±5.32* 38.75±9.37
Neopterin (μM) 4.81±1.12 5.02±1.64 4.70±1.10 5.69±3.15
Data are expressed as mean ± standard deviation or as median and IQR percentile. SMS: multiple sclerosis patients in a stable phase of disease;
BT-AMS: AMS patients before the initiation of glucorticoids; DT-AMS: AMS patients after the initiation of glucorticoids; HC: healthy controls. SE: standard
error;
* p<0.05 compared to HC;
# p<0.05 compared to DT-AMS;
¶ p<0.05 compared to BT-AMS
doi:10.1371/journal.pone.0130715.t002
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Discussion
The biochemical processes leading to the catabolism of the essential amino acid Trp, i.e. the
kynurenine pathway, play an important role in immune regulation. IDO, the key enzyme in
this pathway, is ubiquitously expressed at low level in mammal cells, and cellular mechanisms
responsible for its activation and regulation are not fully elucidated [21], although several its
inducers are well-known, like IFN-γ and LPS [9, 22].
The demonstration that IDO expression plays a role in the remission of acute MS in the
EAE animal model of MS suggested the possibility that this enzyme could be involved in regu-
lating the clinical course of disease [12]; we thus decided to evaluated the expression profile of
IDO and IFN-γ and the enzymatic activity of IDO (Kyn/Trp ratio) in correlation with clinical
features in RR-MS patients. Moreover we measured the neopterin level in serum, a protein that
reflects release of IFN-γ due to the immune system activation [23].
These parameters were analyzed in PBMCs and sera from patients during the clinical
relapse of MS, before and during GC treatment. Data herein show that IDO and IFN-γmRNA
expression as well as serum concentration of neopterin change in patients with acute or stable
MS. Thus, during disease relapses, IDO in lymphocytes and serum neopterin were increased
and IFN-γ was greatly diminished compared to the values observed in the stable phases of dis-
ease. Ethical reasons prevented the possibility to analyze the spontaneous dynamic pattern of
expression of target genes during the entire acute phase in patients. Data herein nevertheless
show that GC-based therapy resulted in a prompt suppression not only of IFN-γ, in accordance
with what was observed previously [24], but also of the expression of IDO. However, because
obvious ethical reasons prevent us to withhold immunosuppressive therapy in patients in
Fig 2. Kynurenine-to-Tryptophan ratio. Kyn/Trp in sera of multiple sclerosis patients with stable (SMS) or
relapsing (AMS) disease and healthy controls (HC). AMS patients were analyzed before (BT-AMS) or after
(DT-AMS) the initiation of glucocorticoid treatment. *p<0.05.
doi:10.1371/journal.pone.0130715.g002
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whom disease relapses occur, at least in theory it cannot be excluded that the observed modifi-
cations in IFN-γ and IDO levels occur naturally and spontaneously, and are not caused by GC.
In our analyses high levels of IDO expression as well as increased serum concentrations of
neopterin were observed in RR-MS in concomitance with the appearance of clinical signs of
disease relapse, indicating that an inflammatory response is indeed taking place in these
patients. IFN-γ expression at the same time point was, on the other hand, down- regulated, in
apparent contrast with previous results [24–27].
A possible explanation for the discrepancy between our data and those shown in [24–27] is
that the peak of IFN-γ production precedes the clinical appearance of disease relapse. The bio-
logical process underlying disease activity does indeed precede clinical symptoms, as MRI
results show that active lesions are detected before the clinical symptoms of MS relapse become
evident [28]. Nevertheless, because MS is a Th1 and Th17 mediated disease, we cannot exclude
that Th17 cytokines could suppress IFN-γ expression.
Our data nevertheless support recent results showing that discordant patterns of IDO and
IFN-γmRNA expression are present in lymph nodes, spinal cord and PBMCs through the pre-
clinical, acute and remission phases of EAE [12].
The evaluation of IDO enzyme activity, calculated as Kyn/Trp ratio in serum, was a subse-
quent and necessary step for a correct interpretation of our results, as gene transcription is not
sufficient to drive the enzyme activity. Surprisingly, analyses of the catalytic activity showed
that the serum Kyn/Trp ratio was increased in MS patients undergoing disease relapse com-
pared to what observed in the stable phases of MS, this activity was decreased upon initiation of
GC, as expected given the known immunosuppressive effect of GC. Notably, GC resulted in a
much more evident decrease of IDO gene expression compared to the Kyn/Trp ratio; this effect
could be due to GC-mediated activation of other enzymes involved in Trp catabolism, such as
tryptophan 2,3-dioxygenase (TDO) [29]. The observed modifications in gene expression and in
the functional activity of IDO could, nevertheless, be also justified by post-translational modifi-
cations, the presence of natural IDO inhibitors (such as NO), the absence of co-factors (such as
hemin), or, finally, structural and conformational aspects of substrate recognition [21, 30, 31].
IDO activation is suggested to be a self-protective response to alleviate autoaggressive CNS
inflammation. This process results in immune suppression as a consequence of the depletion of
Trp [32], and following the direct effect of catabolites (i.e. kynurenines) that inhibit the prolifer-
ation of auto-reactive T lymphocytes and increase their susceptibility to apoptosis [33]. Notably,
IDO expression in dendritic cells promotes the conversion of naive T lymphocytes into Treg
cells; such cells modulate immunotolerance and immunoregulation [34]. These observations
led to the concept that an impairment in the IDO pathway could be involved in the develop-
ment of autoimmune disease including MS, and resulted in the idea that modulation of IDO
expression and activity could be beneficial in autoimmunity. Importantly, activation of Tregs
was suggested to correlate with disease remission in MS thus reinforcing the speculation that
IDO activity does play a role in modulating the clinical phenotype of this disease [35, 36]. A
role for IDO depletion was suggested in the remission of symptoms in EAE [12] as reduced
IFN-γ and increased IDOmRNA were observed in quiescent EAE, indicating that a higher
enzyme activity could result in the depletion of auto-reactive and IFN-γ -producing T lympho-
cytes. A contribution of IDO to disease remission was also indicated by the relapses observed in
mice after treatment with 1-methyl-thriptophane, an IDO inhibitor. These results raised the
possibility that manipulating kynurenine pathway could be a way to treat MS relapse [12].
To our knowledge, this is the first in-depth evaluation of IDO expression and activity in
PBMCs in relation to the clinical course of MS. It is important to underline that our results
reflect the in vivo situation as they were obtained by evaluating mRNA expression in unstimu-
lated lymphocytes. Ethical reasons did not allow following the behaviour of the IDO pathway
IDO in Multiple Sclerosis
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during the relapsing phase, as GC therapy was initiated as soon as the patients were referred to
the hospital. Notably, our results do not totally agree with those obtained in the animal model
[12], probably because EAE model is not completely reproducible in humans.
In conclusion our data indicate that, in accordance with what was observed in the animal
models, IDO could contribute to remission of relapse in MS. These findings raise the possibility
that evaluation of IDO gene expression could be a useful predictive biomarker indicating the
development of flares of disease, thus helping the promptly treatment of such flares, to reduce not
only disease progression, but also related-disease cost and psychological effects for MS patients.
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